The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SQ3370 in patients with cancer (solid tumors).
Overal Status | Start Date | Phase | Study Type |
---|---|---|---|
Recruiting | August 1, 2020 | Phase 1 | Interventional |
Primary Outcome 1 - Measure: Safety and tolerability of SQ3370, including determination of the maximum tolerated dose and the recommended Phase 2 dose.
Primary Outcome 1 - Time Frame: 35 Days
Criteria:
Inclusion Criteria:
- Diagnosis of an advanced local or metastatic solid tumor
- Adequate hematologic, hepatic, renal, and coagulation function
- Tumor is a type where published clinical data would suggest is responsive to
anthracyclines
Exclusion Criteria:
- Prior exposure to 225 mg/m^2 of Dox HCl or DOXIL / CAELYX ® or 450 mg/m^2 of
epirubicin HCl.
- CHF, severe myocardial insufficiency, or cardiac arrhythmia
- Any of the following within 28 days prior to Cycle 1 Day 1:
- Major surgery, as defined by the Investigator
- Radiotherapy
- Chemotherapy (except for small molecule kinase inhibitors, which are 6
elimination half-lives)
- Currently enrolled in or discontinued from a clinical study involving an
investigational agent or non-approved use of a drug or device, or concurrently
enrolled in any other type of medical research judged not to be scientifically or
medically compatible with this study.
Show More
Gender: All
Minimum Age: 18 Years
Maximum Age: N/A
Healthy Volunteers: No
Name: Shasqi Clinical Operations
Phone: 415-800-1376
Email: clinicalstudies@shasqi.com
Facility | Status | Contact |
---|---|---|
Stanford Cancer Center Palo Alto, California 94304 United States |
Recruiting |
Principal Investigator 415-800-1376 clinicalstudies@shasqi.com |
Henry Ford Hospital Detroit, Michigan 48202 United States |
Recruiting |
Principal Investigator 415-800-1376 clinicalstudies@shasqi.com |
MD Anderson Cancer Center Houston, Texas 77030 United States |
Recruiting |
Vivek Subbiah, MD 713-563-0393 VSubbiah@mdanderson.org |
Chris O'Brien Lifehouse Camperdown, New South Wales 2050 Australia |
Recruiting |
Principal Investigator 415-800-1376 clinicalstudies@shasqi.com |
Royal North Shore Hospital Sydney, New South Wales 2065 Australia |
Recruiting |
Principal Investigator 415-800-1376 clinicalstudies@shasqi.com |